WORCESTER, Mass., May 16, 2016 (GLOBE NEWSWIRE) -- Nemucore Medical Innovations, Inc., a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women’s cancers, today announced the election of Nicholas De Monico to its Board of Directors. He brings significant financial experience with a focus on creating economic value for mission-driven organizations.
“We are extremely pleased to have Nick De Monico join Nemucore’s leadership team,” said Timothy P. Coleman, Ph.D., Chairman, Chief Executive Officer, and President of Nemucore. “Not only does he share Nemucore’s vision of building a patient-centric company developing a pipeline of new, much-needed therapeutics addressing women’s multidrug-resistant cancers, but he also brings extensive financial expertise to our Board that should prove invaluable as we grow and advance this pipeline.”
“I have a strong desire to work with mission-based organizations,” said Mr. De Monico. “I firmly believe that Nemucore is that type of organization, a company and team focused on the goal of developing treatments that could forever change the lives of women living with cancer. I also believe that Nemucore’s remarkable dedication to women’s healthcare will resonate with many people in the non-profit and philanthropic communities, particularly with those who identify with the undeniable need for new therapies to address these devastating cancers.”
Mr. De Monico brings more than 35 years of experience in the investment management industry to the Nemucore board, including portfolio management and the management of proprietary trading and asset allocation businesses.
Most recently Mr. De Monico was Chief Investment Officer for the Commonfund, as well as Chief Executive Officer and Head of Investments for the Commonfund Hedge Fund Strategies Group. Prior, he was a Managing Director and Portfolio Manager for Citigroup Alternative Investments, and the Executive Vice President and Treasurer for CDC Capital, a subsidiary of the Caisse Des Depots Group. His experience covers a broad range of functions within the investment management industry: asset allocation, risk management, product design, operations, and client sales and service. Mr. De Monico received an MBA in finance and marketing from Columbia University’s Graduate School of Business and a BA in political science from Columbia College.
About Nemucore Medical Innovations, Inc.
Nemucore Medical Innovations, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women’s cancers. Nemucore's most advanced candidate NMI-900, a potential therapeutic for the treatment of ovarian cancer, is expected to begin a Phase 2 clinical trial in mid-2016. Two additional candidates are anticipated to enter clinical trial development targeting a variety of other difficult-to-treat oncology indications. For more information, please visit our website at www.Nemucore.com.
Contacts: Tim Coleman (investors) Nemucore Medical Innovations (508) 762-1017 BCC Partners (media) Karen Bergman (650) 575-1509 email@example.com Jen LaVin (207) 360-0473 firstname.lastname@example.org
Source:Nemucore Medical Innovations, Inc.